By admin 
Half a century on, the story looks more complicated. Pauling was wrong in important ways, but he was not entirely wrong. Modern research is giving vitamin C a second look in cancer, and it turns out that under certain conditions it can behave less like a gentle vitamin and more like a drug. This complex narrative underscores the often-circuitous path of scientific discovery, where initial enthusiasm, subsequent dismissal, and eventual re-evaluation can reshape our understanding of medical interventions.
Linus Pauling’s towering intellect and groundbreaking contributions to science are undeniable. He was awarded the Nobel Prize in Chemistry in 1954 for his research into the nature of the chemical bond, work that profoundly influenced fields from chemistry to molecular biology. Eight years later, in 1962, he received the Nobel Peace Prize for his campaign against nuclear weapons, making him the only person to ever win two unshared Nobel Prizes. Such a monumental career naturally endowed him with immense authority and public trust. However, it also set the stage for the dramatic controversy that would define the latter part of his life.
By the 1970s, Pauling, then in his seventies, began to champion the therapeutic potential of megadoses of vitamin C, not just for the common cold, but for a far more formidable foe: cancer. His advocacy was met with a mixture of public fascination and profound skepticism from the medical establishment. The “halo effect” — the cognitive bias where a person’s positive traits in one area lead to positive judgments about their other, unrelated traits — was frequently invoked by critics. The prevailing view was that Pauling, a genius in theoretical chemistry, had strayed into an area where his expertise did not apply, leading him down a path of unscientific belief. His eventual death from cancer at the age of 93, despite his lifelong adherence to high-dose vitamin C, seemed to many to be the ultimate, ironic proof of his misjudgment.
Pauling’s vitamin C story began in the 1970s, when he teamed up with the Scottish surgeon Dr. Ewan Cameron. Cameron, working at the Vale of Leven Hospital in Scotland, had been exploring the use of vitamin C in cancer patients, observing promising anecdotal results. Together, they conducted observational studies involving patients with advanced, incurable cancers. Their protocol involved administering very large amounts of vitamin C, initially as a drip directly into a vein (intravenously, or IV), followed by continuous oral doses in tablet form. The results, published in the Proceedings of the National Academy of Sciences and later detailed in their book Cancer and Vitamin C, were remarkably positive. Compared with historical control groups of similar patients who did not receive vitamin C, they reported that the vitamin-treated group lived significantly longer and experienced a better quality of life. For some patients, they suggested, survival could be several times longer than expected, fueling immense hope and excitement.
The scientific community, however, demanded rigorous, reproducible evidence. To test these claims, the Mayo Clinic, a leading non-profit medical center in the US renowned for its research and clinical excellence, initiated two large, randomized, placebo-controlled trials in the late 1970s and early 1980s. These trials, led by Dr. Charles Moertel, were designed to be definitive. Patients with advanced cancer were randomized to receive either high-dose oral vitamin C (10 grams per day) or a placebo. The results, published in the New England Journal of Medicine, were unambiguous: there was no discernible benefit. Patients who took vitamin C pills lived no longer than those who didn’t, nor did they report improved quality of life. For most oncologists, these findings were conclusive. Vitamin C was summarily dismissed and filed away with other “alternative” remedies, and Pauling’s late-career crusade was widely seen as a sad, if understandable, scientific detour. The Mayo Clinic studies effectively closed the book on vitamin C for cancer for decades.
What neither trial’s critics nor defenders fully appreciated at the time, however, was a critical methodological difference: Pauling and Cameron had initiated treatment with intravenous vitamin C, followed by oral doses, whereas the Mayo Clinic trials used tablets only. This seemingly minor detail is, in fact, profoundly significant due to the pharmacokinetics of vitamin C. The human gut possesses a limited capacity to absorb vitamin C. Once a modest daily dose (typically around 200-400 mg) is reached, the body’s intestinal transporters, primarily sodium-dependent vitamin C transporter 1 (SVCT1), become saturated. Beyond this point, regardless of how many tablets one swallows, the concentration of vitamin C in the blood plasma levels off. This means that even the 10 grams per day used in the Mayo Clinic trials, while a seemingly large amount, resulted in blood plasma concentrations only marginally higher than those achieved with standard dietary intake, remaining well within physiological ranges.
By contrast, a drip into a vein bypasses the gastrointestinal absorption bottleneck entirely. Intravenous administration can raise blood plasma levels of vitamin C to tens, or even hundreds, of times higher than tablets ever could. These supraphysiological concentrations, reaching millimolar (mM) ranges (e.g., 5-20 mM), are magnitudes beyond what can be achieved orally (typically micromolar, or µM, levels). It is at these extreme, pharmacologic levels that vitamin C starts to behave profoundly differently inside the body, transitioning from its familiar antioxidant role to a pro-oxidant agent, particularly within the unique microenvironment of a tumor.
At everyday, physiological levels, vitamin C, or ascorbate, acts as a crucial antioxidant. It readily donates electrons to neutralize harmful reactive oxygen species (ROS) and free radicals, thereby protecting our cells from oxidative stress and DNA damage. This is its well-established role in maintaining cellular health, supporting immune function, and aiding collagen synthesis. However, at very high concentrations, especially within the tumor microenvironment, vitamin C can undergo a dramatic flip in its biological role.
In laboratory studies and increasingly in preclinical models, high-dose vitamin C, in the presence of redox-active transition metal ions such as iron or copper (which are often found in higher concentrations in tumor tissues), helps generate hydrogen peroxide (H2O2). This process, known as the Fenton reaction, produces a reactive substance that can cause significant damage to cells. Cancer cells, it turns out, seem especially vulnerable to this induced oxidative stress. They are already under considerable metabolic strain due to their rapid, uncontrolled proliferation, often in areas with poor blood supply (hypoxia) and insufficient nutrients. This stressed state leads to an increased production of their own reactive oxygen species and a compromised ability to detoxify them. Their internal “cleanup” systems, designed to manage normal cellular waste and oxidative byproducts, are stretched thin, making them intrinsically more susceptible to additional oxidative insults.
Adding a sudden pulse of externally generated hydrogen peroxide from high-dose vitamin C can push many cancer cells over the edge. The hydrogen peroxide damages their DNA, proteins, and crucial energy-producing machinery (mitochondria), triggering programmed cell death (apoptosis) or other forms of cellular demise. Normal, healthy cells, which are under less metabolic strain and possess more robust antioxidant defenses (such as catalase and glutathione peroxidase enzymes), are far more likely to survive this oxidative onslaught. In this way, very high doses of intravenous vitamin C behave less like a daily nutritional supplement and more like a weak, selective chemotherapy drug, targeting cancer cells while sparing healthy ones. Crucially, the doses needed for this potent pro-oxidant effect cannot be reached with oral tablets, highlighting the critical importance of the administration route.
What the latest evidence shows
In people, the clinical evidence for high-dose intravenous vitamin C in cancer treatment is still early, but increasingly compelling and often nuanced. Small-scale clinical trials have been conducted, administering high-dose vitamin C through a vein to patients with various hard-to-treat cancers, including aggressive types such as ovarian, pancreatic, glioblastoma (a type of brain tumor), and non-small cell lung cancer. So far, a consistent finding across many of these studies is that most patients can receive large doses (e.g., 1.5 grams per kilogram of body weight, multiple times a week) without experiencing serious side-effects. This favorable safety profile is a significant advantage, particularly when compared to conventional chemotherapy agents. However, problems can occur, especially in individuals with pre-existing conditions such as glucose-6-phosphate dehydrogenase (G6PD) deficiency (which can lead to hemolytic anemia) or impaired kidney function. This underscores the point that high-dose intravenous vitamin C is a pharmacologic intervention that requires medical supervision and careful patient selection; it is not a harmless wellness drip to be indiscriminately sold on the high street.
While the efficacy data remain mixed, a few studies suggest that adding vitamin C infusions to standard chemotherapy regimens may offer tangible benefits for some patients. These benefits have included modest improvements in progression-free survival or overall survival, as well as a reduction in the severity of chemotherapy-related side-effects. For example, some trials have indicated that IV vitamin C can mitigate common adverse events like fatigue, nausea, vomiting, and peripheral neuropathy, thereby improving patients’ tolerance to treatment. However, other studies have shown no clear benefit in terms of tumor response or survival outcomes. The trials conducted to date are generally small, often phase I or early phase II, and vary significantly in terms of patient populations, cancer types, vitamin C dosing schedules, and concomitant therapies. This heterogeneity makes it challenging to draw firm, generalizable conclusions across the board. The urgent need for larger, well-designed, randomized controlled trials (RCTs) to definitively assess efficacy remains a critical priority.
One consistent and particularly encouraging signal emerging from the current research is the impact on quality of life. Patients receiving intravenous vitamin C alongside chemotherapy frequently report less fatigue, reduced pain, and fewer side-effects, such as nausea, compared to those receiving chemotherapy alone. For someone battling advanced cancer, where the primary goal may shift from cure to palliation and symptom management, an improved quality of life can be profoundly meaningful, even if it does not represent the sweeping cure Pauling once envisioned. This aspect alone warrants further investigation, as supportive care is an integral component of comprehensive cancer management.
Beyond its direct pro-oxidant effects, lab work also hints at subtler and multifaceted roles for vitamin C in cancer biology. Vitamin C is a vital cofactor for a family of enzymes called dioxygenases, which are involved in critical cellular processes. These include enzymes that influence how our DNA is “marked” and read (epigenetic modifications, such as DNA methylation and histone demethylation), thereby impacting gene expression and cellular differentiation. It also plays a role in how cells divide and how they respond to low oxygen conditions (hypoxia), which is a hallmark of many solid tumors and a key driver of aggressive cancer behavior and treatment resistance.
In some preclinical experiments, high vitamin C levels have been shown to make cancer cells grow less aggressively, reduce their metastatic potential, and increase their sensitivity to conventional treatments like chemotherapy and radiation. There are even early, albeit speculative, suggestions that vitamin C may help modulate the immune system, potentially enhancing its ability to recognize and attack tumors. For instance, some research suggests it might improve T-cell function or reduce the activity of myeloid-derived suppressor cells, which typically inhibit anti-tumor immunity. These avenues of research are actively being explored and could unveil novel therapeutic strategies, either alone or in combination with immunotherapies.
Partly right
So, was Pauling right after all? The fairest and most accurate answer is that he was partly right, for reasons he did not fully understand at the time, and he certainly exaggerated the promise. He was demonstrably wrong to promote oral vitamin C tablets as a powerful cure for established cancer. Large, careful trials, particularly those from the Mayo Clinic, have not found that swallowing high-dose vitamin C helps people with established cancer live longer or significantly improves their outcomes. He was also overly enthusiastic in presenting vitamin C as a near-universal remedy for a multitude of illnesses, an assertion that lacked sufficient scientific backing.
However, he was not entirely wrong to suspect that vitamin C might have a special and distinct role in cancer treatment. He sensed, long before the scientific community had the tools or the understanding to prove it, that very high doses given directly into a vein would behave quite differently from ordinary dietary supplements or even high oral doses. His intuition about the route of administration, though not fully articulated in terms of pharmacokinetic and mechanistic detail, proved to be prescient.
Modern research has unequivocally confirmed that intravenous vitamin C reaches much higher plasma levels in the blood, bypassing the saturable intestinal absorption mechanisms, and that these supraphysiological concentrations have distinct biological effects, including a pro-oxidant, cytotoxic effect on cancer cells. What we do not yet have are large, definitive, randomized, placebo-controlled trials showing that high-dose intravenous vitamin C clearly and consistently prolongs life for most cancer patients across various tumor types. Until we do, it should be seen as an experimental therapy—promising enough to warrant rigorous scientific study, but not yet proven enough to replace standard-of-care therapies. Any use of high-dose intravenous vitamin C for cancer treatment belongs strictly within the confines of well-designed clinical trials or in carefully supervised medical settings where potential benefits are weighed against risks, and patient safety is paramount, rather than in unregulated clinics selling expensive “immune boosts” with unproven claims.
The broader “vitamins in cancer” story continues to evolve, demonstrating the dynamic nature of scientific inquiry. From initial excitement about vitamin D’s role in colorectal cancer prevention to ongoing research into vitamin B3’s potential in reducing skin cancer risk, the field is constantly re-evaluating the therapeutic potential of micronutrients. If the story of vitamin C and cancer teaches us anything, it is that science rarely moves in straight lines. A bold idea, some flawed early studies, a fierce backlash and dismissal, and then, years later, a quieter, more careful return to the question with new tools, new knowledge, and a more nuanced understanding. Pauling may never be fully vindicated in the way he hoped, but neither was he simply deluded. In his enthusiasm, he may have glimpsed a sliver of truth, a profound pharmacological effect, long before the rest of us knew how to look for it with the necessary scientific rigor and understanding of cellular biology.
